Project Grant R41HL180035
Award Date 9/20/25
Completion Date 9/19/26
Dollars Obligated $285K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
West Palm Beach, FL 33408, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), awarded a $309,418 Project Grant to Oleolive, Inc. to develop an inhaled therapy for idiopathic pulmonary fibrosis (IPF). The award, made on September 20, 2025, will support research to repurpose the FDA-approved drug pyrvinium as an inhalation treatment for IPF, a fatal lung disease affecting 40,000 U.S. patients annually. The project aims to...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded Novomedix LLC a $306,872 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel oral small molecule therapeutics for the treatment of progressive pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). The goal is to create a safer and more effective therapy compared to the currently approved drugs, which only slow disease progression and have significant side effects. Novomedix will...
- This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...
- This $489,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support the establishment of a new in vitro lung alveolar epithelial cell organoid model derived from human bronchoalveolar lavage fluid (BALF). The goal is to develop a physiologically relevant model for studying the human innate immune response to Mycobacterium tuberculosis (MTB) infection and evaluate the effects...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $1,013,003 Project Grant to Inhalon Biopharma, Inc. in Morrisville, North Carolina. This funding supports the IND-enabling development of IN-005, an inhaled, muco-trapping monoclonal antibody therapy for the treatment of influenza A infections. The project aims to advance this novel approach of direct respiratory tract delivery to achieve higher...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,013,468 to Inhalon Biopharma, Inc. to advance the development of IN-003PI, a passive immunization treatment against human metapneumovirus (MPV) infections. The funding will support key research activities such as producing GLP-compliant antibody batches, conducting IND-enabling toxicology and efficacy studies, and...
- This $292,279 federal Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) supports Artiam Bio Inc., a small disadvantaged biotechnology company, in validating the APT101 compound for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in an aging murine model. The project aims to evaluate the comparative efficacy of APT101 and investigate the mechanistic effects of the compound on endothelial function in the fibrotic lung, with...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $1,000,000 Project Grant to Vast Therapeutics, Inc. The grant, effective from September 11, 2025 to August 31, 2027, will support the development of a novel nitric oxide-releasing formulation, ALX1, as a treatment for difficult non-tuberculous mycobacterial lung infections. The project aims to evaluate the pharmacokinetics and...
- This federal Project Grant award, valued at $155,227.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project aims to generate proof-of-concept data on a novel strategy to treat Mycobacterium abscessus (MAB) chronic lung disease, which currently has no FDA-approved treatments. The strategy involves using a biofilm disruptor as an adjunct to antibiotics to more effectively...